NASDAQ:ACET
Adicet Bio Inc Stock News
$1.88
-0.225 (-10.71%)
At Close: Apr 24, 2024
Week 17 MDA Breakout Stocks - April 2021: Short-Term Picks To Give You An Edge
07:08am, Sunday, 25'th Apr 2021
Two new breakout stocks for Week 17 with better than 10% short-term upside potential. For only the 2nd time this year, none of the 4 picks broke above 10% this week in the first negative week for the
Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
07:00am, Tuesday, 13'th Apr 2021
MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
04:10pm, Thursday, 11'th Mar 2021
MENLO PARK, Calif. and BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer
Adicet Bio Announces Initiation of its First-in-Human Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma
07:00am, Wednesday, 10'th Mar 2021
MENLO PARK, Calif. and BOSTON, Mass.
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors
04:01pm, Thursday, 04'th Mar 2021
MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer
MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell
Adicet Bio to Participate in Upcoming Investor Conferences
07:00am, Thursday, 11'th Feb 2021
MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other d
Adicet Bio, Inc. Announces Pricing of $135 Million Public Offering of Common Stock and Concurrent Private Placement
07:51am, Wednesday, 10'th Feb 2021
MENLO PARK, Calif. and BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therap
Adicet: Promising 2021 Therapeutic Initiations, Cash Of $108 Million, And New Management
03:49pm, Monday, 28'th Dec 2020
Adicet Bio is a biotechnology company concentrated on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a pre-clinical pipeline of 4 therapeutics c
Adicet Bio (ACET) Surges: Stock Moves 5.9% Higher
09:47am, Friday, 18'th Dec 2020
Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Adicet Bio to Participate in Fireside Chat at JMP Securities Hematology Summit
07:00am, Tuesday, 08'th Dec 2020
MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for can
Adicet Announces Appointment of Dr. Bastiano Sanna to its Board of Directors
07:00am, Tuesday, 01'st Dec 2020
MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therap
Adicet Bio to Participate in Upcoming Investor Conferences
07:00am, Friday, 06'th Nov 2020
MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therap
Adicet Reports Third Quarter 2020 Financial Results and Provides Business Update
04:10pm, Thursday, 05'th Nov 2020
MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therap
